Key statistics
On Friday, Sagimet Biosciences Inc (0O2:FRA) closed at 4.58, 174.25% above the 52 week low of 1.67 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.52 |
|---|---|
| High | 4.58 |
| Low | 4.52 |
| Bid | 4.60 |
| Offer | 4.80 |
| Previous close | 4.96 |
| Average volume | 634.00 |
|---|---|
| Shares outstanding | 32.52m |
| Free float | 29.16m |
| P/E (TTM) | -- |
| Market cap | 180.49m USD |
| EPS (TTM) | -1.79 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 14:25 GMT.
More ▼
- Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
- Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
- Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
- Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
- Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
- Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
- Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
- Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
- Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
More ▼
